文献速递白血病

DNMT3A突变转录本水平在缓解期持续存在且不能预测急性髓系白血病患者结局

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.
PubMed 文献 · Leukemia · 2017-06-23

该研究通过实时定量PCR监测181例携带DNMT3A-R882H/-R882C突变的急性髓系白血病患者的微小残留病,分析1494份样本。诊断时及诱导、巩固后DNMT3A突变转录本水平与复发率或死亡率无关,仅少数患者达到RQ-PCR阴性,多数患者转录本水平持续较高,提示克隆性造血在血液学缓解期持续存在。

要点

  • 诊断时DNMT3A突变转录本水平与临床特征、共存基因突变及生存终点无关。
  • 诱导I后、诱导II后、巩固I后和巩固II后骨髓中DNMT3A突变转录本水平显著高于血液。
  • 仅少数患者达到RQ-PCR阴性,多数患者转录本水平持续较高,与克隆性造血持续存在一致。

核心结论

  • 在携带DNMT3A-R882H/-R882C突变的急性髓系白血病患者中,诊断时及临床相关MRD时间点的DNMT3A突变转录本水平对缓解持续时间和总生存无影响。

研究设计与样本

  • 研究纳入181例携带DNMT3A-R882H/-R882C突变的急性髓系白血病患者,采用实时定量PCR检测1494份样本中的微小残留病。

主要发现

  • 诊断时DNMT3A突变转录本水平与就诊时临床特征、共存基因突变及生存终点均无相关性。
  • Cox回归分析中,骨髓DNMT3A突变转录本水平(log10转换连续变量)与复发率或死亡率无关。
  • 诱导I后(P=0.01)、诱导II后(P=0.05)、巩固I后(P=0.004)和巩固II后(P=0.008),骨髓中DNMT3A突变转录本水平显著高于血液。
  • 在诱导两周期后和治疗结束时,DNMT3A突变转录本水平对缓解持续时间和总生存无影响。
  • 仅少数患者达到RQ-PCR阴性,多数患者DNMT3A突变转录本水平持续较高,与血液学缓解期克隆性造血持续存在一致。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We investigated the prognostic impact of minimal residual disease (MRD) monitoring in acute myeloid leukemia patients harboring DNA methyltransferase 3A-R882H/-R882C mutations (DNMT3Amut). MRD was determined by real-time quantitative PCR (RQ-PCR) in 1494 samples of 181 DNMT3Amut patients. At the time of diagnosis, DNMT3Amut transcript levels did not correlate with presenting clinical characteristics and concurrent gene mutations as well as the survival end points. In Cox regression analyses, bone marrow (BM) DNMT3Amut transcript levels (log10-transformed continuous variable) were not associated with the rate of relapse or death. DNMT3Amut transcript levels were significantly higher in BM than in blood after induction I (P=0.01), induction II (P=0.05), consolidation I (P=0.004) and consolidation II (P=0.008). With regard to the clinically relevant MRD time points, after two cycles of induction and at the end of therapy, DNMT3Amut transcript levels had no impact on the end point remission duration and overall survival. Of note, only a minority of the patients achieved RQ-PCR negativity, whereas most had constantly high DNMT3Amut transcript levels, a finding which is consistent with the persistence of clonal hematopoiesis in hematological remission.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Gaidzik VI, Weber D, Paschka P, et al. DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia. 2017. PMID: 28643785. doi:10.1038/leu.2017.200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。